Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients.

Autor: Trümpelmann S; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Schulte-Mecklenbeck A; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Steinberg OV; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Wirth T; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Fobker M; Central Laboratories, University Hospital Münster, Münster, Germany., Lohmann L; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Lünemann JD; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Gross CC; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Klotz L; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Jazyk: angličtina
Zdroj: Clinical and translational science [Clin Transl Sci] 2022 Jul; Vol. 15 (7), pp. 1606-1612. Date of Electronic Publication: 2022 Mar 04.
DOI: 10.1111/cts.13256
Abstrakt: The impact of distinct disease-modifying therapies (DMTs) on severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune-responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre-vaccination and 6 weeks post second SARS-CoV-2 vaccination. Healthy individuals and interferon beta-treated patients generated robust humoral and cellular immune-responses. Although humoral immune responses were diminished in ocrelizumab-treated patients, cellular immune-responses were reduced in natalizumab-treated patients. Thus, both humoral and cellular immune responses should be closely monitored in patients on DMTs. Whereas patients with a poor cellular immune-response may benefit from additional vaccination cycles, patients with a diminished humoral immune-response may benefit from a treatment with SARS-CoV-2 antibodies in case of an infection.
(© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje